



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>C07H 21/04, C07K 1/00,</b> <b>C12N 5/00, C12N 9/00,</b> <b>C12N 15/00, C12N 15/87</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/63227</b> <b>(43) International Publication Date:</b> 26 October 2000 (26.10.2000)
<b>(21) International Application Number:</b> PCT/US00/10539 <b>(22) International Filing Date:</b> 19 April 2000 (19.04.2000) <b>(30) Priority Data:</b> 09/294,841 20 April 1999 (20.04.1999) US <b>(60) Parent Application or Grant</b> SMITHKLINE BEECHAM CORPORATION [/]; Q. ZHU, Yuan [/]; Q. LI, Xiaotong [/]; Q. ARNOLD, Anne, Romanic [/]; Q. ARLETH, Anthony, J. [/]; Q. ANDERSEN, Robert, L. ; Q.		<b>Published</b>
<b>(54) Title: A SPLICING VARIANT OF HUMAN MEMBRANE-TYPE MATRIX METALLOPROTEINASE-5 (MT-MMP5-L)</b> <b>(54) Titre: VARIANTE D'EPISSAGE DE METALLOPROTEINASE-5 (MT-MMP5-L) DE MATRICE HUMAINE DE TYPE</b> <b>MEMBRANE</b>  <b>(57) Abstract</b> <p>The MT-MMP5-L polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing MT-MMP5-L polypeptides and polynucleotides in therapy, and diagnostic assays for such.</p> <b>(57) Abrégé</b> <p>Cette invention concerne les polypeptides MT-MMP5-L, les polynucléotides et des techniques permettant de produire ces polypeptides par des technique de recombinaison. Cette invention concerne aussi des techniques d'utilisation de polypeptides MT-MMP5-L et de polynucléotides dans une thérapie, et dans des recherches diagnostiques à cet effet.</p>		

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> C07H 21/04, C07K 1/00, C12N 5/00, 9/00, 15/00, 15/87	<b>A1</b>	<b>(11) International Publication Number:</b> WO 00/63227 <b>(43) International Publication Date:</b> 26 October 2000 (26.10.00)
<b>(21) International Application Number:</b> PCT/US00/10539 <b>(22) International Filing Date:</b> 19 April 2000 (19.04.00)  <b>(30) Priority Data:</b> 09/294,841 20 April 1999 (20.04.99) US  <b>(71) Applicant:</b> SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US).  <b>(72) Inventors:</b> ZHU, Yuan; 203 Oakmont Drive, Blue Bell, PA 19422 (US). LI, Xiaotong; 332 Sugartown Road #B41B, Devon, PA 19333 (US). ARNOLD, Anne, Romanic; 807 Dover Road, Wynnewood, PA 19096 (US). ARLETH, Anthony, J.; 3351 Roxbury Road, Hatfield, PA 19440 (US).  <b>(74) Agents:</b> ANDERSEN, Robert, L. et al.; Ratner & Prestia, 301 One Westlakes (Berwyn), P.O. Box 980, Valley Forge, PA 19482-0980 (US).		<b>(81) Designated States:</b> JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> A SPLICING VARIANT OF HUMAN MEMBRANE-TYPE MATRIX METALLOPROTEINASE-5 (MT-MMP5-L)  <b>(57) Abstract</b>  The MT-MMP5-L polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing MT-MMP5-L polypeptides and polynucleotides in therapy, and diagnostic assays for such.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Description**

5

10

15

20

25

30

35

40

45

50

55

## A Splicing Variant of Human Membrane-Type Matrix Metalloproteinase-5 (MT-MMP5-L)

### Field of the Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

### Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces 'functional genomics', that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on 'positional cloning'. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterize further genes and their related polypeptides/proteins, as targets for drug discovery.

Membrane-Type Matrix Metalloproteinases (MT-MMPs) are a new family of transmembrane matrix metalloproteinases. At present, there are four human MT-MMPs published in the literature (Sato, H. et al., Nature 370:61-65, 1994; Will, H. and Hinzmann, B. Eur. J. Biochem. 231:602-608, 1995; Takino, T. et al., J. Biol. Chem. 270:23013-23020; Puente, X.S. et al., Cancer Res. 56:944-949, 1996). Recently, a fifth MT-MMP (MT-MMP-5) has been published for mouse (Pei, D., J. Biol. Chem. 274:8925-8932, 1999). Also, a splice variant for human MT-MMP-5 in which the catalytic domain is missing has been patented (U.S. Patent Number 5,937,508).

MT-MMPs function as both a receptor and as an activator for certain MMPs and serve to localize extracellular matrix proteolysis at the pericellular region. MT-MMPs have been shown to play a role in metastasis and have been identified in numerous carcinomas. An MT-MMP has also been demonstrated to be involved in Alzheimer's Disease where it has been found in white matter microglia (Yamada, T. et al., Acta Neuropathol. 90: 421-424, 1995). MT-MMPs may also play a role in the infiltration of inflammatory cells. By Northern Array Grid Analysis, MT-MMP5-L expression was detected in cerebellum and kidney. A multiple tissue Northern blot was also probed for MT-MMP5-L where it was identified in brain, kidney and pancreas. This indicates that these Membrane-Type Matrix Metalloproteinase have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of Membrane-Type

- 2 -

Matrix Metalloproteinase family which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, 1) kidney-related diseases including diabetes, polycystic kidney disease, renal failure, etc., 2) brain-related diseases including Alzheimer's disease, stroke multiple sclerosis, neurodegenerative diseases, etc., 3) cardiovascular diseases including restenosis, myocardial infarction, dilated cardiomyopathy, atherosclerosis, etc., and 4) others such as inflammation and cancer.

#### Summary of the Invention

The present invention relates to MT-MMP5-L, in particular MT-MMP5-L polypeptides and MT-MMP5-L polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of 1) kidney-related diseases including diabetes, polycystic kidney disease, renal failure, etc., 2) brain-related diseases including Alzheimer's disease, stroke multiple sclerosis, neurodegenerative diseases, etc., 3) cardiovascular diseases including restenosis, myocardial infarction, dilated cardiomyopathy, atherosclerosis, etc., and 4) others such as inflammation and cancer, hereinafter referred to as "the Diseases", amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with MT-MMP5-L imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate MT-MMP5-L activity or levels.

#### Description of the Invention

In a first aspect, the present invention relates to MT-MMP5-L polypeptides. Such peptides include isolated polypeptides comprising an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

5 Polypeptides of the present invention are believed to be members of the MT-MMP family of polypeptides. They are therefore of interest because MT-MMPs have been shown to play a role in metastasis and have been identified in numerous carcinomas. An MT-MMP has also been  
10 demonstrated to be involved in Alzheimer's Disease where it has been found in white matter microglia (Yamada, T. et al., Acta Neuropathol. 90: 421-424, 1995). MT-MMPs may also play a role in the infiltration of inflammatory cells. These properties are hereinafter referred to as "MT-MMP5-L activity" or "MT-MMP5-L polypeptide activity" or "biological activity of MT-MMP5-L".  
15 Also included amongst these activities are antigenic and immunogenic activities of said MT-MMP5-L polypeptides, in particular the antigenic and immunogenic activities of the polypeptide of SEQ ID NO:2. Preferably, a polypeptide of the present invention exhibits at least one biological activity of MT-MMP5-L.  
20

The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences,  
25 sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.  
30

The present invention also includes include variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any  
35 combination.

Polypeptides of the present invention can be prepared in any suitable manner. Such  
40 polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to MT-MMP5-L polynucleotides. Such  
45 polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those  
50 with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide

comprising the nucleotide sequence contained in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:2.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to SEQ ID NO:1 over the entire length of SEQ ID NO:1. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 as well as the polynucleotide of SEQ ID NO:1.

The invention also provides polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of SEQ ID NO:1 shows homology with human MT-MMP3 and mouse MT5-MMP (D.Pei, JBC, 274:8925-8932, 1999). The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 306 to 1901) encoding a polypeptide of 532 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of SEQ ID NO:2 is structurally related to other proteins of the MT-MMP family, having homology and/or structural similarity with human MT-MMP3 and mouse MT5-MMP (D.Pei, JBC, 274:8925-8932, 1999).

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one MT-MMP5-L activity.

Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human brain, using the expressed



sequence tag (EST) analysis (Adams, M.D., *et al. Science* (1991) 252:1651-1656; Adams, M.D. *et al., Nature*, (1992) 355:632-634; Adams, M.D., *et al., Nature* (1995) 377 Supp:3-174).

Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al., Proc Natl Acad Sci USA* (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Further embodiments of the present invention include polynucleotides encoding polypeptide variants which comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.

Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to SEQ ID NO:1. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that of the referent. The probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the

5 skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, 10 shared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the 5 present invention also includes polynucleotides obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.

15 The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is cut short at the 5' end of the cDNA. This 10 is a consequence of reverse transcriptase, an enzyme with inherently low 'processivity' (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), 20 failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.

25 There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid 15 Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. 30 In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then 20 carried out to amplify the 'missing' 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, 35 that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing 25 and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence 40 information for the design of the 5' primer.

45 Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a 30 further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. 50 Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., *Basic Methods in Molecular Biology* (1986) and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *streptococci*, *staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL* (*supra*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction,

5 anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction  
10 chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography.  
Most preferably, high performance liquid chromatography is employed for purification. Well known  
15 techniques for refolding proteins may be employed to regenerate active conformation when the  
5 polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic  
15 reagents. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1  
which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a  
20 diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-  
10 expression or altered expression of the gene. Individuals carrying mutations in the gene may be  
25 detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine,  
saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may  
25 be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or  
15 cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size  
of the amplified product in comparison to the normal genotype. Point mutations can be identified by  
30 hybridizing amplified DNA to labeled MT-MMP5-L nucleotide sequences. Perfectly matched  
sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in  
melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic  
20 mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing  
(e.g., Myers *et al.*, *Science* (1985) 230:1242). Sequence changes at specific locations may also be  
35 revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage  
method (see Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401). In another embodiment, an  
25 array of oligonucleotides probes comprising MT-MMP5-L nucleotide sequence or fragments thereof  
can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods  
40 are well known and have general applicability and can be used to address a variety of questions in  
molecular genetics including gene expression, genetic linkage, and genetic variability (see for example:  
M.Chee *et al.*, *Science*, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the  
45 30 Diseases through detection of mutation in the MT-MMP5-L gene by the methods described. In  
addition, such diseases may be diagnosed by methods comprising determining from a sample derived  
from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or  
50 increased expression can be measured at the RNA level using any of the methods well known in the  
art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for

instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly 1) kidney-related diseases including diabetes, polycystic kidney disease, renal failure, etc. 2) brain-related diseases including Alzheimer's disease, stroke multiple sclerosis, neurodegenerative diseases, etc. 3) cardiovascular diseases including restenosis, myocardial infarction, dilated cardiomyopathy, atherosclerosis, etc. 4) others such as inflammation and cancer, amongst others.

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected

individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

The gene of the present invention maps to human chromosome 22q13.1.

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, pp. 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against polypeptides of the present invention may also be employed to treat the Diseases, amongst others.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides

5 encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

10 Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention,  
5 adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned, amongst others. Yet another aspect of the invention relates to a  
15 method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce  
10 antibody to protect said animal from diseases.

20 A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a  
25 polypeptide or polynucleotide of the present invention. The vaccine formulation may further  
15 comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal  
30 injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which  
20 render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be  
35 presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately  
prior to use. The vaccine formulation may also include adjuvant systems for enhancing the  
immunogenicity of the formulation, such as oil-in water systems and other systems known in the art.  
25 The dosage will depend on the specific activity of the vaccine and can be readily determined by  
40 routine experimentation.

Polypeptides of the present invention are responsible for many biological functions, including  
many disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirous to devise  
45 screening methods to identify compounds which stimulate or which inhibit the function of the  
30 polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide. In  
general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for such  
Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for  
50 example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists,

antagonists or inhibitors so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, *Current Protocols in Immunology* 1(2):Chapter 5 (1991)).

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring MT-MMP5-L activity in the mixture, and comparing the MT-MMP5-L activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and MT-MMP5-L polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, *J Mol Recognition*, 8:52-58 (1995); and K. Johanson *et al.*, *J Biol Chem*, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical



5 techniques such as surface plasmon resonance and spectroscopy. These screening methods may also  
be used to identify agonists and antagonists of the polypeptide which compete with the binding of  
10 the polypeptide to its receptors, if any. Standard methods for conducting such assays are well  
understood in the art.

5 Examples of potential polypeptide antagonists include antibodies or, in some cases,  
oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc.,  
15 as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes,  
etc.; or small molecules which bind to the polypeptide of the present invention but do not elicit a  
response, so that the activity of the polypeptide is prevented.

10 Thus, in another aspect, the present invention relates to a screening kit for identifying  
agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present  
invention; or compounds which decrease or enhance the production of such polypeptides, which  
comprises:

- 25 (a) a polypeptide of the present invention;  
15 (b) a recombinant cell expressing a polypeptide of the present invention;  
(c) a cell membrane expressing a polypeptide of the present invention; or  
30 (d) antibody to a polypeptide of the present invention;  
which polypeptide is preferably that of SEQ ID NO:2.

35 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial  
20 component.

40 It will be readily appreciated by the skilled artisan that a polypeptide of the present  
invention may also be used in a method for the structure-based design of an agonist, antagonist or  
inhibitor of the polypeptide, by:

- 45 (a) determining in the first instance the three-dimensional structure of the polypeptide;  
25 (b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist,  
antagonist or inhibitor;  
(c) synthesizing candidate compounds that are predicted to bind to or react with the deduced binding  
45 or reactive site; and  
(d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors.

50 30 It will be further appreciated that this will normally be an interactive process.

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, 1) kidney-related diseases including diabetes, polycystic kidney disease, renal failure, etc. 2) brain-related diseases including Alzheimer's disease, stroke multiple sclerosis, neurodegenerative diseases, etc. 3) cardiovascular diseases including restenosis, myocardial infarction, dilated cardiomyopathy, atherosclerosis, etc. 4) others such as inflammation and cancer, related to either an excess of, or an under-expression of, MT-MMP5-L polypeptide activity.

15  
20  
25  
30  
35  
40  
45  
50  
55

If the activity of the polypeptide is in excess, several approaches are available. One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the MT-MMP5-L polypeptide.

15  
20  
25  
30  
35  
40  
45  
50  
55

In still another approach, expression of the gene encoding endogenous MT-MMP5-L polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered (see, for example, O'Connor, *J Neurochem* (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Alternatively, oligonucleotides which form triple helices with the gene can be supplied (see, for example, Lee *et al.*, *Nucleic Acids Res* (1979) 6:3073; Cooney *et al.*, *Science* (1988) 241:456; Dervan *et al.*, *Science* (1991) 251:1360). These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*.

15  
20  
25  
30  
35  
40  
45  
50  
55

For treating abnormal conditions related to an under-expression of MT-MMP5-L and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of MT-MMP5-L by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and

expression of the polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, *Gene Therapy and other Molecular Genetic-based Therapeutic Approaches*, (and references cited therein) in *Human Molecular Genetics*, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex*

vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as GCC. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO:1 and/or a polypeptide sequence encoded thereby.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as

discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)

Gap Penalty: 12

## Gap Length Penalty: 4

A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ ID NO:1, and  $y$  is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is

less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \cdot y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2, and  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

#### Examples

##### 1) Cloning of Full Length Human MT-MMP5-L

Based on the partial EST sequence (HGS, clone HCE3P83), a full-length cDNA clone was isolated by screening a human brain library using PCR method. In order to confirm the start codon, a Lamda clone containing the genomic sequence of human MT-MMP5-L was isolated from a human placenta genomic library. Therefore, the 5' UTR sequence, which contains several stop codons, was revealed from the genomic clone, and confirmed by RT-PCR of human brain mRNA. By comparison with the mouse MT5-MMP (D. Pei, JBC 274:8925-8932, 1999), the human MT-MMP5-L we claim here has a 82 amino acid deletion which encodes a signal peptide and a propeptide domain at the N-



- 21 -

terminus, but it contains a complete catalytic domain. Thus, we define the sequence of the present invention as a splicing variant of human MT-MMP5.

## 2) Biological Studies of human MT-MMP5-L

Western Blot analysis was conducted in protein extracts of various human tissues (Clontech Human Protein Medleys) using polyclonal antibodies generated against peptide fragments unique for MT-MMP-5 and not present in MT-MMP-1, -2, -3, or -4. Protein expression was detected in brain, kidney and heart. Western analysis was also conducted to evaluate MT-MMP-5 protein expression in normal and diabetic human kidney tissues. Results demonstrate significant up-regulation of MT-MMP-5 protein expression in the diabetic kidney samples (n=8, each condition).

## Claims

5

10

15

20

25

30

35

40

45

50

55

**What is claimed is:**

## 1. An isolated polypeptide selected from the group consisting of:

(i) an isolated polypeptide comprising an amino acid sequence selected from the group having at least:

- (a) 70% identity;
- (b) 80% identity;
- (c) 90% identity; or
- (d) 95% identity;

to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2;

(ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2; or

(iii) an isolated polypeptide which is the amino acid sequence of SEQ ID NO:2.

## 2. An isolated polynucleotide selected from the group consisting of:

(i) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least

- (a) 70% identity;
- (b) 80% identity;
- (c) 90% identity; or
- (d) 95% identity;

to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2;

(ii) an isolated polynucleotide comprising a nucleotide sequence that has at least:

- (a) 70% identity
- (b) 80% identity;
- (c) 90% identity; or
- (d) 95% identity;

- 23 -

over its entire length to a nucleotide sequence encoding the polypeptide of SEQ ID NO:2;

(iii) an isolated polynucleotide comprising a nucleotide sequence which has at least:

(a) 70% identity;

(b) 80% identity;

(c) 90% identity; or

(d) 95% identity;

to that of SEQ ID NO: 1 over the entire length of SEQ ID NO:1;

(iv) an isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2;

(v) an isolated polynucleotide which is the polynucleotide of SEQ ID NO: 1; or

(vi) an isolated polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof;

or a nucleotide sequence complementary to said isolated polynucleotide.

3. An antibody immunospecific for the polypeptide of claim 1.

4. A method for the treatment of a subject:

(i) in need of enhanced activity or expression of the polypeptide of claim 1 comprising:

(a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and/or

(b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence encoding said polypeptide in a form so as to effect production of said polypeptide activity *in vivo*; or

(ii) having need to inhibit activity or expression of the polypeptide of claim 1 comprising:

(a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or

- 24 -

(b) administering to the subject a nucleic acid molecule that inhibits the expression of a nucleotide sequence encoding said polypeptide; and/or

(c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate, or receptor.

5. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the polypeptide of claim 1 in a subject comprising:

(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and/or

(b) analyzing for the presence or amount of said polypeptide expression in a sample derived from said subject.

6. A method for screening to identify compounds which stimulate or which inhibit the function of the polypeptide of claim 1 which comprises a method selected from the group consisting of:

(a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

(b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide;

(d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or

(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay.

7. An agonist or an antagonist of the polypeptide of claim 1.

5

10

8. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression system is present in a compatible host cell.

15

5 9. A process for producing a recombinant host cell comprising transforming or transfecting a cell with the expression system of claim 8 such that the host cell, under appropriate culture conditions, produces a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2.

20

10 10. A recombinant host cell produced by the process of claim 9.

25

11. A membrane of a recombinant host cell of claim 10 expressing a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2.

15

30

12. A process for producing a polypeptide comprising culturing a host cell of claim 10 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.

35

40

45

50

55

## SEQUENCE LISTING

&lt;110&gt; SmithKline Beecham Corporation

<120> A SPLICING VARIANT OF HUMAN MEMBRANE-TYPE  
MATRIX METALLOPROTEINASE-5 (MT-MMP5-L)

&lt;130&gt; GH-70613WO

&lt;140&gt; TO BE ASSIGNED

&lt;141&gt; 2000-04-19

&lt;150&gt; 09/294,841

&lt;151&gt; 1999-04-20

&lt;160&gt; 2

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 1923

&lt;212&gt; DNA

&lt;213&gt; HOMO SAPIENS

&lt;400&gt; 1

ccgtttctag	caggagggga	caccaataaa	agctgctctc	tggagatgaa	tttggcagtg	60
tctgcaggat	ggggtgaagg	aaaaagaact	cagagcatga	gtccaggagt	cactggggtc	120
aaatgatccc	tcgtgttcaa	ggcacatctc	tgcccaggta	gaacagagcc	tctcccagca	180
taacgcacct	ttttctttcc	cgtgtctttc	agaactgggt	aaagtccctat	ggctatctgc	240
ttccctatga	ctcacgggca	tctgcgctgc	actcagcgaa	ggccttgag	tcggcagctc	300
ccactatgca	gcagttttac	gggatcccg	tcaccgggtg	gttggatcag	acaacgatcg	360
agtggatgaa	gaaaccccg	tgtggtgtcc	ctgatcacc	ccacttaagc	cgtaggcgga	420
gaaacaagcg	ctatgccctg	actggacaga	agtggaggca	aaaacacatc	acctacagca	480
ttcacacta	taccccaaaa	gtgggtgagc	tagacacgcg	gaaagctatt	cgccaggctt	540
tcgatgtgtg	gcagaagggtg	acccactga	cctttgaaga	gggtgccatac	catgagatca	600
aaagtgaccg	gaaggaggca	gacatcatga	tcttttttgc	ttctgggttc	catggcgaca	660
gctccccatt	tgatggagaa	gggggattcc	tggcccatgc	ctacttcctt	ggcccaggga	720
ttggaggaga	caccactttt	gactccgatg	agccatggac	gctaggaaat	gccaaacctg	780
acgggaacga	cctcttcctg	gtggctgtgc	atgagctggg	ccacgcgctg	ggactggagc	840
actccagcga	ccccagcgcc	atcatggcgc	ccttctacca	gtacatggag	acgcacaaat	900
tcaagctgcc	ccaggacgat	ctccagggca	tccagaagat	ctatggaccc	ccagccgagc	960
ctctggagcc	cacaaggcca	ctccctacac	tccccgtccg	caggatccac	tcaccatcgg	1020
agaggaaaca	cgagcgccag	cccaggcccc	ctcggccgcc	cctcggggac	cggccatcca	1080
caccaggcac	caaaccacaac	atctgtgacg	gcaacttcaa	cacagtggcc	ctcttccggg	1140
gcgagatggt	tgtctttaag	gacgctgggt	tctggcgctc	gcgcaataac	cgagtgcagg	1200
agggtacccc	tatgcagatc	gagcagttct	ggaagggcct	gcctgcccg	atcgacgcag	1260
cctatgaaag	ggccgatggg	agatttgtct	tcttcaaagg	tgacaagtat	tggtgtttta	1320
aggaggtgac	ggtggagcct	gggtaccccc	acagcctggg	ggagctgggc	agctgtttgc	1380
cccgtgaagg	cattgacaca	gctctgcgct	gggaacctgt	gggcaagacc	tactttttca	1440
aaggcgagcg	gtactggcgc	tacagcgagg	agcggcgggc	cacggaccct	ggctacccta	1500
agcccatcac	cgtgtggaag	ggcatcccac	aggctcccca	aggagccttc	atcagcaagg	1560
aaggatatta	cacctatttc	tacaaggggc	gggactactg	gaagtctgac	aaccagaaac	1620
tgagcgtgga	gccaggctac	ccgcgcaaca	tcttgcgtga	ctggatgggc	tgcaaccaga	1680
aggaggtgga	gcggcggaag	gagcggcggc	tgccccagga	cgacgtggac	atcatggtga	1740
ccatcaacga	tgtgccgggc	tccgcgaacg	ccgtggccgt	ggtcatcccc	tgcatcctgt	1800
ccctctgcat	cctggtgctg	gtctacacca	tcttccagtt	caagaacaag	acaggccctc	1860
agcctgtcac	ctactataag	cggccagtcc	aggaaatgggt	gtgagcagcc	cagagccctc	1920

tct

1923

<210> 2  
 <211> 532  
 <212> PRT  
 <213> HOMO SAPIEN

<400> 2

Met Gln Gln Phe Tyr Gly Ile Pro Val Thr Gly Val Leu Asp Gln Thr  
 1 5 10 15  
 Thr Ile Glu Trp Met Lys Lys Pro Arg Cys Gly Val Pro Asp His Pro  
 20 25 30  
 His Leu Ser Arg Arg Arg Arg Asn Lys Arg Tyr Ala Leu Thr Gly Gln  
 35 40 45  
 Lys Trp Arg Gln Lys His Ile Thr Tyr Ser Ile His Asn Tyr Thr Pro  
 50 55 60  
 Lys Val Gly Glu Leu Asp Thr Arg Lys Ala Ile Arg Gln Ala Phe Asp  
 65 70 75 80  
 Val Trp Gln Lys Val Thr Pro Leu Thr Phe Glu Glu Val Pro Tyr His  
 85 90 95  
 Glu Ile Lys Ser Asp Arg Lys Glu Ala Asp Ile Met Ile Phe Phe Ala  
 100 105 110  
 Ser Gly Phe His Gly Asp Ser Ser Pro Phe Asp Gly Glu Gly Gly Phe  
 115 120 125  
 Leu Ala His Ala Tyr Phe Pro Gly Pro Gly Ile Gly Gly Asp Thr His  
 130 135 140  
 Phe Asp Ser Asp Glu Pro Trp Thr Leu Gly Asn Ala Asn His Asp Gly  
 145 150 155 160  
 Asn Asp Leu Phe Leu Val Ala Val His Glu Leu Gly His Ala Leu Gly  
 165 170 175  
 Leu Glu His Ser Ser Asp Pro Ser Ala Ile Met Ala Pro Phe Tyr Gln  
 180 185 190  
 Tyr Met Glu Thr His Asn Phe Lys Leu Pro Gln Asp Asp Leu Gln Gly  
 195 200 205  
 Ile Gln Lys Ile Tyr Gly Pro Pro Ala Glu Pro Leu Glu Pro Thr Arg  
 210 215 220  
 Pro Leu Pro Thr Leu Pro Val Arg Arg Ile His Ser Pro Ser Glu Arg  
 225 230 235 240  
 Lys His Glu Arg Gln Pro Arg Pro Pro Arg Pro Pro Leu Gly Asp Arg  
 245 250 255  
 Pro Ser Thr Pro Gly Thr Lys Pro Asn Ile Cys Asp Gly Asn Phe Asn  
 260 265 270  
 Thr Val Ala Leu Phe Arg Gly Glu Met Phe Val Phe Lys Asp Arg Trp  
 275 280 285  
 Phe Trp Arg Leu Arg Asn Asn Arg Val Gln Glu Gly Tyr Pro Met Gln  
 290 295 300  
 Ile Glu Gln Phe Trp Lys Gly Leu Pro Ala Arg Ile Asp Ala Ala Tyr  
 305 310 315 320  
 Glu Arg Ala Asp Gly Arg Phe Val Phe Phe Lys Gly Asp Lys Tyr Trp  
 325 330 335  
 Val Phe Lys Glu Val Thr Val Glu Pro Gly Tyr Pro His Ser Leu Gly  
 340 345 350  
 Glu Leu Gly Ser Cys Leu Pro Arg Glu Gly Ile Asp Thr Ala Leu Arg  
 355 360 365  
 Trp Glu Pro Val Gly Lys Thr Tyr Phe Phe Lys Gly Glu Arg Tyr Trp  
 370 375 380  
 Arg Tyr Ser Glu Glu Arg Arg Ala Thr Asp Pro Gly Tyr Pro Lys Pro  
 385 390 395 400  
 Ile Thr Val Trp Lys Gly Ile Pro Gln Ala Pro Gln Gly Ala Phe Ile





## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/10539

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : C07H 21/04; C07K 1/00; C12N 5/00, 9/00, 15/00, 15/87 US CL : 435/183, 320.1, 325, 440, 455; 530/350; 536/23.1, 23.2 According to International Patent Classification (IPC) or to both national classification and IPC																								
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/183, 320.1, 325, 440, 455; 530/350; 536/23.1, 23.2  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST2.0, MEDLINE, BIOSIS, CAPLUS, GENCORE																								
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																								
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																						
A	US 5,837,508 A (ARNOLD et al) 17 November 1998 (17/11/98), see entire document.	1-12																						
A	PEI, D. Identification and Characterization of the Fifth Membrane-type Matrix Metalloproteinase MTS-MMP. Journal of Biological Chemistry. 26 March 1999, Vol. 274, No. 13, pages 8925-8932, see entire document.	1-12																						
X	Database Genbank, Accession No. AJ010262, 25 March 1999, PEI, D., 'Identification and characterization of the fifth membrane-type matrix metalloproteinase MTS-MMP'. Journal of Biological Chemistry. 26 March 1999, Vol. 274, No. 13, pages 8925-8932, see entire document.	1-12																						
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																								
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to underpin the principle or theory underlying the invention</td></tr><tr><td>*A</td><td>document defining the general state of the art which is not considered to be of particular relevance</td><td></td></tr><tr><td>*B</td><td>earlier document published on or after the international filing date</td><td>*X</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*L</td><td>document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*Y</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*O</td><td>document referring to an oral disclosure, use, exhibition or other means</td><td>*A</td><td>document member of the same patent family</td></tr><tr><td>*P</td><td>document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to underpin the principle or theory underlying the invention	*A	document defining the general state of the art which is not considered to be of particular relevance		*B	earlier document published on or after the international filing date	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*L	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*O	document referring to an oral disclosure, use, exhibition or other means	*A	document member of the same patent family	*P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to underpin the principle or theory underlying the invention																						
*A	document defining the general state of the art which is not considered to be of particular relevance																							
*B	earlier document published on or after the international filing date	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																					
*L	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																					
*O	document referring to an oral disclosure, use, exhibition or other means	*A	document member of the same patent family																					
*P	document published prior to the international filing date but later than the priority date claimed																							
Date of the actual completion of the international search 20 JULY 2000		Date of mailing of the international search report 01 AUG 2000																						
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Carrie Stroup</i> CARRIE STROUP Telephone No. (703) 308-0196																						

Form PCT/ISA/210 (second sheet) (July 1998)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/10539

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenCore, Accession No. P51512, 15 July 1998, TAKINO et al, 'Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family'. Journal of Biological Chemistry. September 1995, Vol. 270, No. 39, pages 23013-23020, see entire document.	1-12
X	Database GenCore, Accession No. Q98947, 01 February 1997, YANG et al, 'Cloning and developmental expression of a membrane-type matrix metalloproteinase from chicken'. Journal of Biological Chemistry. October 1996, Vol. 271, No. 41, pages 25548-25554, see entire document.	1-12